Optinose

Quote

















Great news you have a second product to try to sell!
Complete failure by Peter on all levels.

Optinose (NASDAQ: OPTN) today announced the Company received written notice from Avanir Pharmaceuticals, Inc. of its election to terminate the License Agreement to develop and commercialize ONZETRA® XSAIL® in the United States, Canada, and Mexico. As a result, the License Agreement is expected to terminate on March 10, 2019.

Upon termination of the license agreement, Optinose may elect to continue to commercialize ONZETRA XSAIL itself or through a new licensee.

“Optinose intends to evaluate its options with respect to the future of ONZETRA XSAIL,” stated CEO Peter Miller. “What is important is that we believe the termination of the license agreement will not have a material effect on the Company’s use of cash. Our strategic focus is on building a leading company to serve the unmet needs of ENT and Allergy Specialists and their patients. As a result, we intend to focus on options for ONZETRA XSAIL that involve minimal organizational burden for Optinose, which may include identifying and licensing ONZETRA XSAIL to a new partner.”

Through September 30, 2018, under the terms of the License Agreement with Avanir, Optinose has received aggregate cash payments of $70 million in connection with the initial signing and subsequent payments.
 








the death of the licensing ONZETRA® XSAIL® agreement with Avanir is a big deal. We were counting on them to take the burden of development-both $$ and time off our plates- so we could focus on our in line product. This says two things:
1) the product doesn't have a future or
2) if it does we
a) have to it ourselves or
b) find a new partner

Scenario 1 is a HUGE problem
Scenario 2 is a cash flow problem.

Hence the reason for the further stanking today! Nice job Peter and Ramy!
 








Never had the displeasure of meeting Kelly. I am, however, acquainted with several of the current Optinose employees, one quite well. I can only say that Peter's secretary... you know, his barometer of "nice", could not possibly be more wrong in her assessment of the personalities of those folks. In particular, the former J & J failures that are currently staffing Optinose are anything but nice. Let's charitably say that many of them have personality disorders, more than are morally challenged, and at least one is a full blown sociopath. Congratulations, Peter, you have done a fine job of putting this company together.
 
































































































































Top Bottom
Back
Quote